MedPage Today -- BALTIMORE -- Eslicarbazepine acetate (Stedesa), a European anti-epileptic drug not yet licensed in the U.S., reduced seizure frequency and was well tolerated as an add-on treatment in patients with refractory partial-onset seizures in a trial reported here.
